The so-called Genome Browser in the Cloud offers the same capabilities as the web-based version of the resource but is easier to install.
The company, which is working on its own genetic test, provides customers with nutrition and lifestyle recommendations based on their genotyping profiles.
In addition to variant detection technology, Omicia also gets technologies like data compression, which will aid diagnostics development and data storage.
The Houston- and Slovenia-based data firm wants to boot scientists off Excel spreadsheets and onto its flexible, proprietary platform for data management.
Cancer genomics firm Tempus' pact with Cleveland's UH Seidman Cancer Center adds to its list of partnerships with academic oncology centers.
As SpeeDx preps for the European launch of its STI tests, it will incorporate UgenTec's automated data analysis tool for PCR applications.
The company also extended its existing licensing agreement with Genalice, signed in 2013, to improve plant DNA analysis.
Objectives for this year include building a network of ELIXIR beacons, developing new features and security measures, and partnering with data owners.
Researchers applied their gene genealogy interrogation approach to fish in the otophysan clade before moving on to other branches in the tree of life.
Infoshield's encryption technology promises the ability to perform calculations and computations without having to first decrypt sensitive data.
The cloud-based personalized medicine software company will stay in Cambridge, Massachusetts and will become a wholly-owned subsidiary of the institute.
The software takes somatic mutation profiles from individual patients as input and uses them to prioritize relevant mutations and potential treatments.
The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.
The collaborations aim to combine Illumina's sequencing systems with Philips' IntelliSpace Genomics platform and with IBM's Watson for Genomics, respectively.
The deal, completed this month with cash reserves for an undisclosed price, adds scalability and multi-omics analysis to Qiagen's bioinformatics portfolio.
The Genomics Evidence Neoplasia Information Exchange aims to provide insights through the analysis of data from tens if not hundreds of thousands of patient results.
The bioinformatics startup has also invested in six other companies, committing $400 million to its data-sharing collaboration.
The group published a position statement today advocating for "extensive" sharing of lab and clinical data in order to improve treatment of patients.
The integration provides Thermo Fisher's customers with a comprehensive suite of metagenomic analysis and microbial profiling tools.
The company will develop a data warehouse that integrates whole-genome sequence, medical, and wearables data from patients and controls.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.